Advances in manufacturing, automation, and lentiviral vector technologies are reshaping the future of CAR T therapies. Ex vivo and in vivo approaches will evolve together, helping improve scalability, lower costs, and expand patient access worldwide. The post CAR T Manufacturing Innovation Expands Patient Access appeared first on GEN - Genetic Engineering and Biotechnology News .